{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T02:29:00Z","timestamp":1791599340790,"version":"4.3.4"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T00:00:00Z","timestamp":1732233600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T00:00:00Z","timestamp":1732233600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Heart and Stroke Foundation of Canada"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11883-024-01252-0","type":"journal-article","created":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T06:00:51Z","timestamp":1732255251000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Lp(a): A Rapidly Evolving Therapeutic Landscape"],"prefix":"10.1007","volume":"27","author":[{"given":"Khalil","family":"Anchouche","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Thanassoulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,22]]},"reference":[{"issue":"39","key":"1252_CR1","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","volume":"43","author":"F Kronenberg","year":"2022","unstructured":"Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European atherosclerosis society consensus statement. Eur Heart J. 2022;43(39):3925\u201346.","journal-title":"Eur Heart J"},{"issue":"8","key":"1252_CR2","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1194\/jlr.R067314","volume":"57","author":"K Schmidt","year":"2016","unstructured":"Schmidt K, Noureen A, Kronenberg F, Utermann G. Structure, function, and genetics of lipoprotein (a). J Lipid Res. 2016;57(8):1339\u201359.","journal-title":"J Lipid Res"},{"issue":"2","key":"1252_CR3","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1097\/MOL.0000000000000392","volume":"28","author":"M Afshar","year":"2017","unstructured":"Afshar M, Thanassoulis G. Lipoprotein(a): new insights from modern genomics. Curr Opin Lipidol. 2017;28(2):170\u20136.","journal-title":"Curr Opin Lipidol"},{"issue":"5","key":"1252_CR4","doi-asserted-by":"publisher","first-page":"e002862","DOI":"10.1161\/CIRCGEN.119.002862","volume":"14","author":"NR van Zuydam","year":"2021","unstructured":"van Zuydam NR, Stiby A, Abdalla M, Austin E, Dahlstr\u00f6m EH, McLachlan S, et al. Genome-wide Association study of Peripheral Artery Disease. Circ Genom Precis Med. 2021;14(5):e002862.","journal-title":"Circ Genom Precis Med"},{"issue":"1","key":"1252_CR5","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.jacc.2019.03.524","volume":"74","author":"A Langsted","year":"2019","unstructured":"Langsted A, Nordestgaard BG, Kamstrup PR. Elevated lipoprotein(a) and risk of ischemic stroke. J Am Coll Cardiol. 2019;74(1):54\u201366.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"1252_CR6","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.jchf.2015.08.006","volume":"4","author":"PR Kamstrup","year":"2016","unstructured":"Kamstrup PR, Nordestgaard BG. Elevated lipoprotein(a) levels, LPA risk genotypes, and increased risk of Heart failure in the General Population. JACC Heart Fail. 2016;4(1):78\u201387.","journal-title":"JACC Heart Fail"},{"issue":"6","key":"1252_CR7","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1161\/CIRCULATIONAHA.113.004406","volume":"129","author":"AV Khera","year":"2014","unstructured":"Khera AV, Everett BM, Caulfield MP, Hantash FM, Wohlgemuth J, Ridker PM, et al. Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (justification for the Use of statins in Prevention: an intervention trial evaluating Rosuvastatin). Circulation. 2014;129(6):635\u201342.","journal-title":"Circulation"},{"issue":"11","key":"1252_CR8","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1161\/ATVBAHA.116.308011","volume":"36","author":"S Varvel","year":"2016","unstructured":"Varvel S, McConnell JP, Tsimikas S. Prevalence of Elevated Lp(a) Mass levels and patient thresholds in 532 359 patients in the United States. Arterioscler Thromb Vasc Biol. 2016;36(11):2239\u201345.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"6","key":"1252_CR9","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","volume":"69","author":"S Tsimikas","year":"2017","unstructured":"Tsimikas S. A test in Context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies. J Am Coll Cardiol. 2017;69(6):692\u2013711.","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"1252_CR10","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1001\/jama.2009.801","volume":"301","author":"PR Kamstrup","year":"2009","unstructured":"Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA. 2009;301(22):2331\u20139.","journal-title":"JAMA"},{"issue":"3","key":"1252_CR11","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.tips.2019.01.004","volume":"40","author":"MJ Borrelli","year":"2019","unstructured":"Borrelli MJ, Youssef A, Boffa MB, Koschinsky ML. New frontiers in Lp(a)-Targeted therapies. Trends Pharmacol Sci. 2019;40(3):212\u201325.","journal-title":"Trends Pharmacol Sci"},{"issue":"32","key":"1252_CR12","doi-asserted-by":"publisher","first-page":"9919","DOI":"10.1021\/bi060283t","volume":"45","author":"L Becker","year":"2006","unstructured":"Becker L, Nesheim ME, Koschinsky ML. Catalysis of covalent lp(a) assembly: evidence for an extracellular enzyme activity that enhances disulfide bond formation. Biochemistry. 2006;45(32):9919\u201328.","journal-title":"Biochemistry"},{"issue":"8","key":"1252_CR13","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1001\/jama.2022.13044","volume":"328","author":"UPST Force","year":"2022","unstructured":"Force UPST. Statin use for the primary Prevention of Cardiovascular Disease in adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2022;328(8):746\u201353.","journal-title":"JAMA"},{"issue":"11","key":"1252_CR14","doi-asserted-by":"publisher","first-page":"e2025675","DOI":"10.1001\/jamanetworkopen.2020.25675","volume":"3","author":"M Banach","year":"2020","unstructured":"Banach M, Penson PE, Statins. Secondary Prevention\u2014So much progress, so far to go. JAMA Netw Open. 2020;3(11):e2025675\u2013e.","journal-title":"JAMA Netw Open"},{"issue":"9","key":"1252_CR15","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1161\/ATVBAHA.115.305835","volume":"35","author":"M Croyal","year":"2015","unstructured":"Croyal M, Ouguerram K, Passard M, Ferchaud-Roucher V, Ch\u00e9tiveaux M, Billon-Crossouard S, et al. Effects of extended-release Nicotinic Acid on Apolipoprotein (a) kinetics in hypertriglyceridemic patients. Arterioscler Thromb Vasc Biol. 2015;35(9):2042\u20137.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"24","key":"1252_CR16","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","volume":"365","author":"WE Boden","year":"2011","unstructured":"Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365(24):2255\u201367.","journal-title":"N Engl J Med"},{"issue":"25","key":"1252_CR17","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after Acute Coronary syndromes. N Engl J Med. 2015;372(25):2387\u201397.","journal-title":"N Engl J Med"},{"issue":"1","key":"1252_CR18","doi-asserted-by":"publisher","first-page":"17887","DOI":"10.1038\/s41598-018-36204-7","volume":"8","author":"A Sahebkar","year":"2018","unstructured":"Sahebkar A, Simental-Mend\u00eda LE, Pirro M, Banach M, Watts GF, Sirtori C, et al. Impact of ezetimibe on plasma lipoprotein(a) concentrations as monotherapy or in combination with statins: a systematic review and meta-analysis of randomized controlled trials. Sci Rep. 2018;8(1):17887.","journal-title":"Sci Rep"},{"issue":"18","key":"1252_CR19","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and Clinical outcomes in patients with Cardiovascular Disease. N Engl J Med. 2017;376(18):1713\u201322.","journal-title":"N Engl J Med"},{"issue":"22","key":"1252_CR20","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and Cardiovascular outcomes after Acute Coronary Syndrome. N Engl J Med. 2018;379(22):2097\u2013107.","journal-title":"N Engl J Med"},{"issue":"12","key":"1252_CR21","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","volume":"139","author":"ML O\u2019Donoghue","year":"2019","unstructured":"O\u2019Donoghue ML, Fazio S, Giugliano RP, Stroes ESG, Kanevsky E, Gouni-Berthold I, et al. Lipoprotein(a), PCSK9 inhibition, and Cardiovascular Risk. Circulation. 2019;139(12):1483\u201392.","journal-title":"Circulation"},{"issue":"2","key":"1252_CR22","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jacc.2019.10.057","volume":"75","author":"VA Bittner","year":"2020","unstructured":"Bittner VA, Szarek M, Aylward PE, Bhatt DL, Diaz R, Edelberg JM, et al. Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk after Acute Coronary Syndrome. J Am Coll Cardiol. 2020;75(2):133\u201344.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"1252_CR23","doi-asserted-by":"publisher","first-page":"e347","DOI":"10.1161\/CIR.0000000000001209","volume":"149","author":"SS Martin","year":"2024","unstructured":"Martin SS, Aday AW, Almarzooq ZI, Anderson CAM, Arora P, Avery CL, et al. 2024 Heart Disease and Stroke statistics: a report of US and Global Data from the American Heart Association. Circulation. 2024;149(8):e347\u2013913.","journal-title":"Circulation"},{"issue":"16","key":"1252_CR24","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/j.jacc.2024.03.370","volume":"83","author":"MJ Blaha","year":"2024","unstructured":"Blaha MJ, Bhatia HS. Lipoprotein(a), residual Cardiovascular Risk, and the search for targeted therapy. J Am Coll Cardiol. 2024;83(16):1540\u20132.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"1252_CR25","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1161\/CIRCULATIONAHA.120.053216","volume":"144","author":"M Birger","year":"2021","unstructured":"Birger M, Kaldjian AS, Roth GA, Moran AE, Dieleman JL, Bellows BK. Spending on Cardiovascular Disease and Cardiovascular Risk factors in the United States: 1996 to 2016. Circulation. 2021;144(4):271\u201382.","journal-title":"Circulation"},{"issue":"8","key":"1252_CR26","first-page":"1129","volume":"37","author":"GJ Pearson","year":"2021","unstructured":"Pearson GJ, Thanassoulis G, Anderson TJ, Barry AR, Couture P, Dayan N, et al. 2021 Canadian Cardiovascular Society Guidelines for the management of Dyslipidemia for the Prevention of Cardiovascular Disease in adults. Can J Cardiol. 2021;37(8):1129\u201350.","journal-title":"Can J Cardiol"},{"key":"1252_CR27","unstructured":"Koschinsky ML, Soffer DE, Boffa MB. What\u2019s Next for Lipoprotein(a)? A National Lipid Association Report from an Expert Panel Discussion. Journal of Clinical Lipidology."},{"issue":"12","key":"1252_CR28","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1161\/ATVBAHA.116.308271","volume":"36","author":"M Afshar","year":"2016","unstructured":"Afshar M, Kamstrup PR, Williams K, Sniderman AD, Nordestgaard BG, Thanassoulis G. Estimating the Population Impact of Lp(a) lowering on the incidence of myocardial infarction and aortic stenosis-brief report. Arterioscler Thromb Vasc Biol. 2016;36(12):2421\u20133.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"1252_CR29","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1001\/jamacardio.2023.4115","volume":"9","author":"MG Levin","year":"2024","unstructured":"Levin MG, Burgess S. Mendelian randomization as a Tool for Cardiovascular Research: a review. JAMA Cardiol. 2024;9(1):79\u201389.","journal-title":"JAMA Cardiol"},{"issue":"6","key":"1252_CR30","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa1109034","volume":"368","author":"G Thanassoulis","year":"2013","unstructured":"Thanassoulis G, Campbell CY, Owens DS, Smith JG, Smith AV, Peloso GM, et al. Genetic associations with valvular calcification and aortic stenosis. N Engl J Med. 2013;368(6):503\u201312.","journal-title":"N Engl J Med"},{"issue":"5","key":"1252_CR31","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.jacc.2013.09.038","volume":"63","author":"PR Kamstrup","year":"2014","unstructured":"Kamstrup PR, Tybj\u00e6rg-Hansen A, Nordestgaard BG. Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. J Am Coll Cardiol. 2014;63(5):470\u20137.","journal-title":"J Am Coll Cardiol"},{"issue":"25","key":"1252_CR32","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1016\/j.jacc.2016.10.033","volume":"68","author":"CA Emdin","year":"2016","unstructured":"Emdin CA, Khera AV, Natarajan P, Klarin D, Won HH, Peloso GM, et al. Phenotypic characterization of genetically lowered human lipoprotein(a) levels. J Am Coll Cardiol. 2016;68(25):2761\u201372.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"1252_CR33","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.jacc.2023.10.039","volume":"83","author":"E Bj\u00f6rnson","year":"2024","unstructured":"Bj\u00f6rnson E, Adiels M, Taskinen MR, Burgess S, Chapman MJ, Packard CJ, et al. Lipoprotein(a) is markedly more atherogenic than LDL: an apolipoprotein B-Based genetic analysis. J Am Coll Cardiol. 2024;83(3):385\u201395.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"1252_CR34","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s43856-023-00419-1","volume":"4","author":"MC Lauffer","year":"2024","unstructured":"Lauffer MC, van Roon-Mom W, Aartsma-Rus A, N\u2009=\u2009C. Possibilities and limitations of antisense oligonucleotide therapies for the treatment of monogenic disorders. Commun Med. 2024;4(1):6.","journal-title":"Commun Med"},{"issue":"7","key":"1252_CR35","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1038\/s41587-022-01396-x","volume":"40","author":"C Sheridan","year":"2022","unstructured":"Sheridan C. RNA drugs lower lipoprotein(a) and genetically driven cholesterol. Nat Biotechnol. 2022;40(7):983\u20135.","journal-title":"Nat Biotechnol"},{"issue":"10","key":"1252_CR36","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","volume":"19","author":"TC Roberts","year":"2020","unstructured":"Roberts TC, Langer R, Wood MJA. Advances in oligonucleotide drug delivery. Nat Rev Drug Discov. 2020;19(10):673\u201394.","journal-title":"Nat Rev Drug Discov"},{"issue":"10002","key":"1252_CR37","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1016\/S0140-6736(15)61252-1","volume":"386","author":"S Tsimikas","year":"2015","unstructured":"Tsimikas S, Viney NJ, Hughes SG, Singleton W, Graham MJ, Baker BF, et al. Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study. Lancet. 2015;386(10002):1472\u201383.","journal-title":"Lancet"},{"issue":"10057","key":"1252_CR38","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1016\/S0140-6736(16)31009-1","volume":"388","author":"NJ Viney","year":"2016","unstructured":"Viney NJ, van Capelleveen JC, Geary RS, Xia S, Tami JA, Yu RZ, et al. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. Lancet. 2016;388(10057):2239\u201353.","journal-title":"Lancet"},{"issue":"3","key":"1252_CR39","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1056\/NEJMoa1905239","volume":"382","author":"S Tsimikas","year":"2020","unstructured":"Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, Tardif JC, Baum SJ, Steinhagen-Thiessen E, et al. Lipoprotein(a) reduction in persons with Cardiovascular Disease. N Engl J Med. 2020;382(3):244\u201355.","journal-title":"N Engl J Med"},{"issue":"1","key":"1252_CR40","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/s41591-021-01634-w","volume":"28","author":"MJ Koren","year":"2022","unstructured":"Koren MJ, Moriarty PM, Baum SJ, Neutel J, Hernandez-Illas M, Weintraub HS, et al. Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a). Nat Med. 2022;28(1):96\u2013103.","journal-title":"Nat Med"},{"issue":"20","key":"1252_CR41","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1056\/NEJMoa2211023","volume":"387","author":"ML O\u2019Donoghue","year":"2022","unstructured":"O\u2019Donoghue ML, Rosenson RS, Gencer B, L\u00f3pez JAG, Lepor NE, Baum SJ, et al. Small interfering RNA to reduce lipoprotein(a) in Cardiovascular Disease. N Engl J Med. 2022;387(20):1855\u201364.","journal-title":"N Engl J Med"},{"issue":"21","key":"1252_CR42","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1001\/jama.2023.21835","volume":"330","author":"SE Nissen","year":"2023","unstructured":"Nissen SE, Linnebjerg H, Shen X, Wolski K, Ma X, Lim S, et al. Lepodisiran, an extended-duration short interfering RNA targeting lipoprotein(a): a randomized dose-ascending clinical trial. JAMA. 2023;330(21):2075\u201383.","journal-title":"JAMA"},{"issue":"17","key":"1252_CR43","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1001\/jama.2022.5050","volume":"327","author":"SE Nissen","year":"2022","unstructured":"Nissen SE, Wolski K, Balog C, Swerdlow DI, Scrimgeour AC, Rambaran C, et al. Single ascending dose study of a short interfering RNA targeting lipoprotein(a) production in individuals with elevated plasma lipoprotein(a) levels. JAMA. 2022;327(17):1679\u201387.","journal-title":"JAMA"},{"issue":"11","key":"1252_CR44","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1001\/jama.2023.16503","volume":"330","author":"SJ Nicholls","year":"2023","unstructured":"Nicholls SJ, Nissen SE, Fleming C, Urva S, Suico J, Berg PH, et al. Muvalaplin, an oral small molecule inhibitor of lipoprotein(a) formation: a Randomized Clinical Trial. JAMA. 2023;330(11):1042\u201353.","journal-title":"JAMA"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-024-01252-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11883-024-01252-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-024-01252-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T12:02:30Z","timestamp":1758801750000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11883-024-01252-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,22]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1252"],"URL":"https:\/\/doi.org\/10.1007\/s11883-024-01252-0","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,22]]},"assertion":[{"value":"4 October 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No animal or human subjects were used by the authors in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"Dr. Thanassoulis has received consulting fees from Ionis Pharmaceuticals; and has participated in advisory boards for Amgen, Sanofi, Novartis, HLS Therapeutics, New Amsterdam, Novo Nordisk and Silence. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"7"}}